NCT07361705 2026-01-23Zorifertinib With Osimertinib for NSCLC With Meningeal ProgressionAlpha Biopharma (Jiangsu) Co., Ltd.Phase 1 Not yet recruiting42 enrolled
NCT05120960 2024-04-17A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain TumorsM.D. Anderson Cancer CenterPhase 1 Withdrawn